FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients - Full Text View

Purpose

The purpose of this study is to provide treatment for patients who have chronic lymphocytic leukemia (CLL), and to compare the use of rituximab added to fludarabine+cyclophosphamide (FC) with FC alone, to determine if rituximab lengthens the time a patient remains free of leukemia symptoms.

Condition	Intervention	Phase
Chronic Lymphocytic Leukemia	Drug: Rituximab Drug: Fludarabine Phosphate Drug: Cyclophosphamide	Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Open-label, Multicenter, Randomized, Comparative, Phase III Study to Evaluate the Efficacy and Safety of FCR vs. FC Alone in Previously Treated Patients With CD20 Positive B-cell CLL

Resource links provided by NLM:

MedlinePlus related topics: Chronic Lymphocytic Leukemia Leukemia

Drug Information available for: Fludarabine Fludarabine phosphate

Genetic and Rare Diseases Information Center resources: Chronic Lymphocytic Leukemia Leukemia, B-cell, Chronic

U.S. FDA Resources

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:

Progression-free Survival (PFS) as Assessed by the Independent Review Committee (IRC) [ Time Frame: Mean observation time at time of analysis was approximately 26 months ]
Progression-free survival as assessed by the IRC was defined as the time between randomization and the date of first documented disease progression, relapse after response, or death from any cause, whichever came first. Patients without a PFS event were censored at their last tumor assessment date.
Number of Participants With Progression-free Survival (PFS) Events Assessed by the Independent Review Committee (IRC) [ Time Frame: Mean observation time at time of analysis was approximately 26 months ]
Progression-free survival as assessed by the IRC was defined as the time between randomization and the date of first documented disease progression, relapse after response, or death from any cause (PFS events), whichever came first. Patients without a PFS event were censored at their last tumor assessment date.
Final Analysis: Time to Progression-Free Survival Event [ Time Frame: Median observation time was approximately 5 years ]
Time to progression-free survival (PFS) event was defined as the time between randomization and the date of first documented PFS event: disease progression, relapse or death by any cause, whichever came first.

Secondary Outcome Measures:

Overall Survival (OS) [ Time Frame: Mean observation time at time of analysis was approximately 26 months ]
Overall survival was determined from the date of randomization to the date of death irrespective of cause. Patients who had not died at the time of the final analysis (clinical data cut-off) were censored at the date of the last contact.
Number of Participants With Overall Survival (OS) Events [ Time Frame: Mean observation time at time of analysis was approximately 26 months ]
Overall survival was determined from the date of randomization to the date of death (OS event) irrespective of cause. Patients who had not died at the time of the final analysis (clinical data cut-off) were censored at the date of the last contact.
Event-free Survival (EFS) [ Time Frame: Mean observation time at time of analysis was approximately 26 months ]
Event free survival was measured from the day of randomization to the date of first documented PD, relapse after response, start of a new treatment or death from any cause. Patients without an EFS event were censored at their last tumor assessment date.
Number of Participants With Event-free Survival (EFS) Events [ Time Frame: Mean observation time at time of analysis was approximately 26 months ]
Event free survival was measured from the day of randomization to the date of first documented Progressive Disease (PD), relapse after response, start of a new treatment or death from any cause (EFS events). Patients without an EFS event were censored at their last tumor assessment date.
Disease-free Survival (DFS) [ Time Frame: Mean observation time at time of analysis was approximately 26 months ]
Disease free survival was defined for all patients with a best overall response (BOR) of Complete Response (CR) and measured the time from first documented CR in a sequence of consecutive CRs until documented disease progression, relapse or death from any cause. Patients without a DFS event at the time of the analysis (clinical data cut-off) were censored at their last tumor assessment date.
Number of Participants With Disease-free Survival (DFS) Events [ Time Frame: Mean observation time at time of analysis was approximately 26 months ]
Disease free survival was defined for all patients with a best overall response (BOR) of Complete Response (CR) and measured the time from first documented CR in a sequence of consecutive CRs until documented disease progression, relapse or death from any cause (DFS events). Patients without a DFS event at the time of the analysis (clinical data cut-off) were censored at their last tumor assessment date.
Final Analysis: Time to Overall Survival Event [ Time Frame: Median observation time was approximately 5 years ]
Overall survival (OS) was determined from the date of randomization to the date of death (OS event) irrespective of cause.
Final Analysis: Time to Event-Free Survival Event [ Time Frame: Median observation time was approximately 5 years ]
Event free survival (EFS) was defined as the time from the day of randomization to the date of first EFS event: documented disease progression, relapse after response, start of a new treatment or death from any cause.
Final Analysis: Percentage of Participants With Complete Response [ Time Frame: Median observation time was approximately 5 years ]
Complete response was defined as the disappearance of all signs of cancer in response to treatment.
Final Analysis: Time to Disease-Free Survival Event [ Time Frame: Median observation time was approximately 5 years ]
Time to disease-free survival (DFS) event was defined as the time from first documented response until the first documented DFS event: disease progression, relapse or death from any cause.
Final Analysis: Duration of Response [ Time Frame: Median observation time was approximately 5 years ]
Duration of response was defined as the time between the date of the earliest qualifying response and the date of disease progression or death due to any cause.
Final Analysis: Time to New Chronic Lymphocytic Leukemia (CLL) Treatment [ Time Frame: Median observation time was approximately 5 years ]
Time to new CCL treatment was defined as the time from randomization to the first day of new treatment for CCL or death.


Enrollment:	552
Study Start Date:	July 2003
Study Completion Date:	June 2012
Primary Completion Date:	July 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: Fludarabine+Cyclophosphamide (FC)	Drug: Fludarabine Phosphate Intravenous repeating dose Drug: Cyclophosphamide Intravenous repeating dose
Experimental: Fludarabine+Cyclophosphamide+Rituximab (FCR)	Drug: Rituximab Intravenous repeating dose Drug: Fludarabine Phosphate Intravenous repeating dose Drug: Cyclophosphamide Intravenous repeating dose

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age ≥18 years
Established diagnosis of B-cell CLL by NCI Working Group criteria
≤1 previous line of chemotherapy
Expected survival >6 months
Acceptable hematologic status, liver function, renal function, and pulmonary function
Negative serum pregnancy test for both pre-menopausal women and for women who are < 2 years after the onset of menopause
Written informed consent

Exclusion Criteria:

Prior treatment with interferon, rituximab or other monoclonal antibody
Prior allogeneic bone marrow transplant (BMT) or autologous BMT or peripheral stem cell transplant (PBSCT) or patients who are considered to be candidates for allogeneic or autologous BMT or PSCT as assessed by their treating physician
Fertile men or women of childbearing potential not using adequate contraception
Severe Grade 3 or 4 non-hematological toxicity or prolonged (> 2 weeks) Grade 3 or 4 cytopenia on prior fludarabine or nucleoside analogue regimen
History of fludarabine-induced or clinically significant autoimmune cytopenia
History of other malignancies within 2 years prior to study entry, except for adequately treated carcinoma in situ of the cervix; basal or squamous cell skin cancer; low-grade early stage localized prostate cancer treated surgically with curative intent; good prognosis ductal carcinoma in situ (DCIS) of the breast treated with lumpectomy alone with curative intent.
Medical conditions requiring long term use (> 1 month) of systemic corticosteroids
Active bacterial, viral, or fungal infection requiring systemic therapy
Severe cardiac disease
Seizure disorders requiring anticonvulsant therapy
Severe chronic obstructive pulmonary disease with hypoxemia
Uncontrolled diabetes mellitus or hypertension
Transformation to aggressive B-cell malignancy.
Known infection with HIV, HCV, or hepatitis B
Treatment with any other investigational agent, or participation in another clinical trial within 30 days prior to entering this study
Known hypersensitivity or anaphylactic reactions to murine antibodies or proteins
Any co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00090051

Hide Study Locations

Locations


United States, North Carolina
Research Site
Durham, North Carolina, United States
Australia
Research Site
Concord, Australia
Research Site
East Melbourne, Australia
Research Site
Frankston, Australia
Belgium
Research Site
Antwerpen, Belgium, 2060
Research Site
Bruxelles, Belgium
Research Site
Leuven, Belgium, 3000
Canada, Alberta
Research Site
Edmonton, Alberta, Canada
Canada, British Columbia
Research Site
Vancouver, British Columbia, Canada
Canada, Newfoundland and Labrador
Research Site
St Johns, Newfoundland and Labrador, Canada, A1B 3V6
Canada, Nova Scotia
Research Site
Halifax, Nova Scotia, Canada
Canada, Ontario
Research Site
Hamilton, Ontario, Canada, L8V 5C2
Research Site
Ottawa, Ontario, Canada
Research Site
Toronto, Ontario, Canada, M4N 3M5
Research Site
Toronto, Ontario, Canada
Denmark
Research Site
Aarhus, Denmark
Research Site
Copenhagen, Denmark
France
Research Site
Bobigny, France
Research Site
Caen Cedex, France
Research Site
Clermont Ferrand Cedex 1, France
Research Site
Creteil, France
Research Site
Le Mans, France
Research Site
Lille Cedex, France
Research Site
Lyon Cedex 8, France, 69373
Research Site
Lyon, France
Research Site
Marseille Cedex 9, France, 13273
Research Site
Montpellier Cedex 5, France
Research Site
Nantes Cedex 1, France
Research Site
Paris Cedex 04, France, 75181
Research Site
Paris Cedex 10, France, 75475
Research Site
Paris, France
Research Site
Pierre Benite Cedex, France
Research Site
Rouen, France
Research Site
Tours, France
Research Site
Vandoeuvre, France, 54500
Hungary
Research Site
Budapest, Hungary, H-1122
Research Site
Budapest, Hungary, H-1135
Research Site
Debrecen, Hungary
Research Site
Pecs, Hungary, H-7624
Research Site
Szeged, Hungary, H-6720
Italy
Research Site
Bari, Italy
Research Site
Bologna, Italy
Research Site
Milano, Italy
Research Site
Napoli, Italy
Research Site
Pavia, Italy
Research Site
Roma, Italy, 00144
Research Site
Vicenza, Italy
Netherlands
Research Site
Amersfoort, Netherlands, 3800 BM
Research Site
Amsterdam, Netherlands
Research Site
Den Haag, Netherlands, 2545 CH
Research Site
Rotterdam, Netherlands
New Zealand
Research Site
Auckland, New Zealand
Research Site
Christchurch, New Zealand
Research Site
Wellington South, New Zealand
Norway
Research Site
Oslo, Norway
Poland
Research Site
Lodz, Poland
Research Site
Lublin, Poland
Research Site
Warszawa, Poland, 00-909
Research Site
Warszawa, Poland, 00-957
Research Site
Warszawa, Poland, 02-097
Romania
Research Site
Bucharest, Romania, 022 328
Research Site
Bucharest, Romania, 030 171
Research Site
Tg. Mures, Romania, 540 136
Research Site
Timisoara, Romania, 300 079
Russian Federation
Research Site
Moscow, Russian Federation, 115478
Research Site
Moscow, Russian Federation, 125167
Research Site
Moscow, Russian Federation, 129128
Research Site
Obninsk, Russian Federation, 249036
Research Site
Samara, Russian Federation, 443095
Research Site
St. Petersburg, Russian Federation, 193024
Research Site
St. Petersburg, Russian Federation, 194291
Research Site
St. Petersburg, Russian Federation, 197089
Research Site
St. Petersburg, Russian Federation, 197110
Spain
Research Site
Madrid, Spain, 28006
Research Site
Madrid, Spain, 28041
Research Site
Salamanca, Spain
Research Site
Zaragoza, Spain
Sweden
Research Site
Linkoping, Sweden
Research Site
Stockholm, Sweden
United Kingdom
Research Site
Bournemouth, United Kingdom
Research Site
Cambridge, United Kingdom
Research Site
Glasgow, United Kingdom
Research Site
Leeds, United Kingdom
Research Site
Liverpool, United Kingdom
Research Site
London, United Kingdom, EC1A 7BE
Research Site
London, United Kingdom, SW3 6JJ
Research Site
Wakefield, United Kingdom

Sponsors and Collaborators

Hoffmann-La Roche

Biogen

Genentech, Inc.

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Weisser M, Yeh RF, Duchateau-Nguyen G, Palermo G, Nguyen TQ, Shi X, Stinson SY, Yu N, Dufour A, Robak T, Salogub GN, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, Larratt L, Rossiev VA, Bence-Bruckler I, Geisler CH, Montillo M, Fischer K, Fink AM, Hallek M, Bloehdorn J, Busch R, Benner A, Döhner H, Valente N, Wenger MK, Stilgenbauer S, Dornan D. PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia. Blood. 2014 Jul 17;124(3):420-5. doi: 10.1182/blood-2013-12-538975. Epub 2014 Jun 10.

Dufour A, Palermo G, Zellmeier E, Mellert G, Duchateau-Nguyen G, Schneider S, Benthaus T, Kakadia PM, Spiekermann K, Hiddemann W, Braess J, Truong S, Patten N, Wu L, Lohmann S, Dornan D, GuhaThakurta D, Yeh RF, Salogub G, Solal-Celigny P, Dmoszynska A, Robak T, Montillo M, Catalano J, Geisler CH, Weisser M, Bohlander SK. Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients. Blood. 2013 May 2;121(18):3650-7. doi: 10.1182/blood-2012-10-458695. Epub 2013 Mar 22.


Responsible Party:	Hoffmann-La Roche
ClinicalTrials.gov Identifier:	NCT00090051 History of Changes
Other Study ID Numbers:	102-14 BO17072
Study First Received:	August 23, 2004
Results First Received:	December 22, 2009
Last Updated:	May 29, 2013

Additional relevant MeSH terms:


Leukemia, Lymphocytic, Chronic, B-Cell Rituximab Leukemia Leukemia, Lymphoid Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Leukemia, B-Cell Cyclophosphamide Fludarabine phosphate	Fludarabine Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists Antimetabolites, Antineoplastic Antimetabolites

ClinicalTrials.gov processed this record on June 26, 2017